Clinical trial
Open access
Sep 2026
Immunogenicity and safety of a single dose of adjuvanted RSVPreF3 vaccine in adults ≥60 years of age in China: results from a phase 3 immunobridging trial
A single dose of adjuvanted RSVPreF3 was immunogenic and well tolerated in Chinese adults aged ≥60 years, supporting the extrapolation of global efficacy and a favorable benefit-risk profile in this population.
Xiang Guo, Gui-Jun Ning, D. Bi et al.
· Frontiers in Immunology · 0 citations